Aurora Cannabis Inc. (NYSE:ACB – Get Rating) has earned a consensus rating of “Hold” from the eleven ratings firms that are covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $7.02.
A number of equities research analysts recently issued reports on the company. Zacks Investment Research raised Aurora Cannabis from a “sell” rating to a “hold” rating in a research note on Monday, January 31st. CIBC decreased their price target on Aurora Cannabis from C$9.25 to C$6.50 in a research note on Thursday, February 3rd. Finally, Cantor Fitzgerald decreased their price target on Aurora Cannabis from C$10.75 to C$7.60 in a research note on Friday, February 11th.
Several large investors have recently made changes to their positions in ACB. Amundi Pioneer Asset Management Inc. purchased a new position in shares of Aurora Cannabis in the 1st quarter valued at $768,000. Invesco Ltd. increased its holdings in shares of Aurora Cannabis by 57.0% in the 2nd quarter. Invesco Ltd. now owns 48,427 shares of the company’s stock valued at $438,000 after acquiring an additional 17,583 shares during the period. Advisor Group Holdings Inc. increased its holdings in shares of Aurora Cannabis by 2.9% in the 3rd quarter. Advisor Group Holdings Inc. now owns 60,912 shares of the company’s stock valued at $423,000 after acquiring an additional 1,732 shares during the period. Moors & Cabot Inc. purchased a new position in shares of Aurora Cannabis in the 3rd quarter valued at $291,000. Finally, Aurora Private Wealth Inc. grew its stake in Aurora Cannabis by 19.2% during the 3rd quarter. Aurora Private Wealth Inc. now owns 11,918 shares of the company’s stock worth $82,000 after buying an additional 1,917 shares during the last quarter. Institutional investors and hedge funds own 17.61% of the company’s stock.
Aurora Cannabis (NYSE:ACB – Get Rating) last issued its quarterly earnings results on Thursday, February 10th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.25). Aurora Cannabis had a negative return on equity of 11.52% and a negative net margin of 167.83%. The business had revenue of $48.07 million for the quarter, compared to the consensus estimate of $45.87 million. As a group, analysts expect that Aurora Cannabis will post -0.8 earnings per share for the current fiscal year.
Aurora Cannabis Company Profile (Get Rating)
Aurora Cannabis Inc produces, distributes, and sells cannabis and cannabis derivative products in Canada and internationally. It also engages in facility engineering and design, cannabis breeding, research, production, derivatives, product development, wholesale, and retail distribution activities. The company produces various strains of dried cannabis, cannabis oil and capsules, and topical kits for medical patients.
- Get a free copy of the StockNews.com research report on Aurora Cannabis (ACB)
- Xerox Holdings Stock is a Value Play
- Carl Icahn Buys More Xerox
- The Kraft Heinz Turnaround Story Gains Momentum
- Microsoft (NASDAQ: MSFT) Saves The Day, For Now
- Las Vegas Sands Stock Could be a Winning Bet Down Here
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.